Connect with us

Healthcare Buzz

Brinton Pharmaceuticals receives Series B funding from India Alternatives

India Alternatives Investment Advisors Ltd. has invested up to USD 8 million for a significant minority stake in Brinton Pharmaceuticals Limited. Among the fastest-growing companies in the Indian pharmaceutical market, Brinton is focused on dermatology and has recently expanded into the pediatric dermatology and respiratory segments. This transaction marks the second investment in Brinton by an institutional investor, following Tata Capital Healthcare Fund’s investment in 2017.

Rahulkumar Darda
Chairman & Managing Director,
Brinton Pharmaceuticals

“We are excited to partner with an investor of the caliber of India Alternatives and strongly believe this association will bring synergies and help us continue our profitable growth journey. This investment will enhance our capabilities in formulations and research and development for niche areas of dermatology and cosmetology, and support expansion of the company’s footprint within India as well as globally.”

Copyright © 2024 Medical Buyer

error: Content is protected !!